2022
DOI: 10.1101/2022.10.17.512378
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Targeting the BAG-1 family of co-chaperones in lethal prostate cancer

Abstract: Therapies that abrogate persistent androgen receptor (AR) signaling in castration resistant prostate cancer (CRPC) remain an unmet clinical need. The N-terminal domain (NTD) of the AR drives transcriptional activity in CRPC but is intrinsically disordered and remains a challenging therapeutic target. Therefore, inhibiting critical co-chaperones, such as BAG-1L, is an attractive alternative strategy. We performed druggability analyses demonstrating the BAG domain to be a challenging drug target. Thio-2, a tool … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 65 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?